Table 1. Baseline characteristics of patients with P. aeruginosa bacteremia.
| n | median | % | IQR | |
|---|---|---|---|---|
| Demographics | ||||
| Age | 66 | 51–76 | ||
| Male gender | 128 | 68.5% | ||
| Underlying conditions | ||||
| Charlson comorbidity index | 3 | 2–4 | ||
| Intravenous drug use | 17 | 9.1% | ||
| Immunosuppression | 89 | 47.6% | ||
| Solid organ transplant | 3 | 1.6% | ||
| Allogenic stem cell transplant | 13 | 7.0% | ||
| Autologous stem cell transplant | 5 | 2.7% | ||
| Neutropenia at diagnosis | 31 | 16.6% | ||
| Clinical presentation | ||||
| PITT bacteremia score | 1 | 0–2 | ||
| Septic shock | 20 | 10.7% | ||
| ICU admission* | 71 | 38.0% | ||
| Mechanical ventilation | 13 | 7.0% | ||
| Microbiological features | ||||
| Number of positive blood cultures | 2 | 0–2 | ||
| Polymicrobial sepsis | 70 | 37.4% | ||
| Origin of bacteremia | ||||
| Urinary tract | 42 | 22.5% | ||
| Unknown | 39 | 20.9% | ||
| Vascular catheter | 34 | 18.2% | ||
| Respiratory tract | 31 | 16.6% | ||
| Abdominal | 16 | 8.6% | ||
| Skin/soft tissue | 12 | 6.4% | ||
| Surgical site infection | 6 | 3.2% | ||
| Bone/joint | 4 | 2.1% | ||
| Pancreaticobiliary | 3 | 1.6% | ||
| Treatment | ||||
| Adequate empirical treatment | 151 | 80.7% | ||
| Piperacillin/tazobactam | 77 | |||
| Piperacillin/tazobactam + aminoglycoside | 13 | |||
| Piperacillin/tazobactam + ciprofloxacin | 3 | |||
| Piperacillin/tazobactam + aminoglycoside/ciprofloxacin |
2 | |||
| Cefepime | 6 | |||
| Cefepime + aminoglycoside | 12 | |||
| Cefepime + ciprofloxacin | 1 | |||
| Imipenem | 2 | |||
| Imipenem + aminoglycoside | 2 | |||
| Meropenem | 12 | |||
| Meropenem + aminoglycoside | 5 | |||
| Meropenem + ciprofloxacin | 2 | |||
| Ciprofloxacin | 12 | |||
| Levifloxacin | 2 | |||
| Inadequate empirical treatment | 36 | 19.25% | ||
| Amoxicillin/clavulanic acid** | 21 | 11.23% | ||
| Ceftriaxone | 15 | 8.02% | ||
| Adequate definite combination treatment | 80 | 42.8% | ||
| Betalactam and fluoroquinolone combination | 19 | |||
| Betalactam and aminoglycoside combination | 61 | |||
| Adequate definite single-drug treatment | 107 | 57.2% | ||
| Total duration of antibiotic treatment (days) | 15 | 12–20 | ||
| Outcome | ||||
| Death during hospital stay | 33 | 17.7% | ||
| Death attributable to bacteremia | 28 | 15.0% |
ICU: intensive care unit
*Among 71 patients admitted to the ICU, 15 patients were admitted to the ICU within the first few hours after bacteremia, as they presented with septic shock.
** intravenous formulation